PB2035: CAMMA 3: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF SUBCUTANEOUS CEVOSTAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA. (23rd June 2022) - Delimpasi, S.; Quach, H.; Cavo, M.; Ho, P. J.; Lee, C. H.-S.; Santoro, A.; Schots, R.; Vlummens, P.; Yoon, D. H.; Yoon, S.-S.; Santos, C. D.; Samineni, D.; et al.